Literature DB >> 15618742

Uptake mechanism of pitavastatin, a new inhibitor of HMG-CoA reductase, in rat hepatocytes.

Syunsuke Shimada1, Hideki Fujino, Takashi Morikawa, Matsuko Moriyasu, Junji Kojima.   

Abstract

To understand the mechanism underlying the highly liver-selective distribution of pitavastatin, uptake experiments were performed using rat hepatocytes. The uptake of pitavastatin into rat hepatocytes is carrier-mediated and involved nonspecific diffusion in the presence of Na(+). The michaelis constant (K(m)) was 26.0 micromol/L, maximal uptake velocity (V(max)) was 3124 pmol/min/mg protein, and non-specific uptake (P(dif)) was 1.16 microL/min/mg protein. There were no remarkable differences in these kinetic parameters between the presence and absence of Na(+). Experiments using metabolic inhibitors revealed that energy-dependent systems contribute to the uptake of pitavastatin in the liver. Some organic anions reduced the uptake into rat hepatocytes in a concentration-dependent manner. The observed rates of inhibition of pitavastatin uptake by BSP, TCA and pravastatin were compared with the predicted rates. The predicted values were calculated, assuming that BSP, TCA and pravastatin inhibit the uptake of pitavastatin in a competitive manner. The observed inhibition by BSP and TCA was similar to that predicted, but the observed inhibition by pravastatin was considerably less than that predicted. In conclusion, most of the pitavastatin taken up into the liver is transported by multiple carrier-mediated transporters such as Na(+)-independent multispecific anion transporters and energy-dependent transporters. In addition, these systems for pitavastatin may have features in common with the BSP and TCA transport system, and may partially involve the pravastatin transport system.

Entities:  

Year:  2003        PMID: 15618742     DOI: 10.2133/dmpk.18.245

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  4 in total

1.  The Presence of a Transporter-Induced Protein Binding Shift: A New Explanation for Protein-Facilitated Uptake and Improvement for In Vitro-In Vivo Extrapolation.

Authors:  Christine M Bowman; Hideaki Okochi; Leslie Z Benet
Journal:  Drug Metab Dispos       Date:  2019-01-23       Impact factor: 3.922

2.  An S-warfarin and AZD1981 interaction: in vitro and clinical pilot data suggest the N-deacetylated amino acid metabolite as the primary perpetrator.

Authors:  Ken Grime; Rikard Pehrson; Pär Nordell; Michael Gillen; Wolfgang Kühn; Timothy Mant; Marie Brännström; Petter Svanberg; Barry Jones; Clive Brealey
Journal:  Br J Clin Pharmacol       Date:  2016-10-13       Impact factor: 4.335

Review 3.  Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia.

Authors:  Sean T Duggan
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

Review 4.  Benefit-risk assessment of pitavastatin for the treatment of hypercholesterolemia in older patients.

Authors:  Kevin W Chamberlin; William L Baker
Journal:  Clin Interv Aging       Date:  2015-04-16       Impact factor: 4.458

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.